ClinicalTrials.gg
CompletedNCT02412449Updated Nov 14, 2018

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

A Phase 1 interventional study of AKB-6548 tablet, reference formulation given in the fasted state and AKB-6548 tablet, test formulation given in the fasted state. in Healthy, sponsored by Akebia Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Akebia Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
21st of 27
18 · median 60
Started
2015
with 1 other
Phase 1
4 of 27
none open now
Registered
7th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 21st largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 1, and was the 7th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the PK parameters of a single dose of a test tablet formulation of AKB-6548 relative to a single dose of the reference AKB-6548 tablet formulation, both treatments administered without food, and to compare the PK parameters of the test tablet formulation given under fed and fasted conditions.

03

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • Anemia
  • Chronic kidney disease
  • CKD
  • Renal impairment
  • Chronic renal insufficiency
  • Ferrous sulfate
  • Iron
  • End stage renal disease
  • Dialysis
  • Oral anemia treatment
  • Bioavailability
  • Erythropoietin
  • Hypoxia-inducible factor
  • Volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects between 18 and 55 years of age, inclusive, and with a between 18 and 30 kg/m2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Current or past history of cardiovascular, cerebrovascular, pulmonary, renal or liver disease.
  • Positive serology results for , , and at Screening.
  • Significant renal impairment as evidenced by an estimated (eGFR) of \<65 mL/min
  • Known active cancer (except non-melanoma skin cancer) or history of chemotherapy use within the previous 24 months.
  • Current or past history of gastric or duodenal ulcers or other diseases of the GI tract (including gastric bypass surgeries) that could interfere with absorption of study drug.
  • Subjects with a known history of smoking and/or have used nicotine or nicotine-containing products within the past 6 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment A

    AKB-6548

    Drug: AKB-6548 tablet, reference formulation given in the fasted state

  • Experimental
    Treatment B

    AKB-6548

    Drug: AKB-6548 tablet, test formulation given in the fasted state.

  • Experimental
    Treatment C

    AKB-6548

    Drug: AKB-6548 tablet, test formulation given in the fed state

06

What researchers measure

Primary outcomes

  1. Bioavailability endpoints: Area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUC 0-t) of AKB-6548

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  2. Bioavailability endpoints: Area under the concentration time curve from time 0 to infinity (AUC 0-inf) of AKB-6548

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  3. Bioavailability endpoints: Maximum observed plasma concentration (Cmax) of AKB-6548

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  4. Food Effect Endpoint: AKB-6548 AUC 0-t for the fed versus fasted administration of AKB-6548 tablets

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  5. Food Effect Endpoint: AKB-6548 AUC 0-inf for the fed versus fasted administration of AKB-6548 tablets

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  6. Food Effect Endpoint: AKB-6548 Cmax for the fed versus fasted administration of AKB-6548 tablets

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

Secondary outcomes

  1. PK Parameters of AKB-6548: Maximum observed plasma concentration (Cmax)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  2. PK Parameters of AKB-6548: Time to reach Cmax (Tmax)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  3. PK Parameters of AKB-6548: Terminal elimination rate constant (λz)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  4. PK Parameters of AKB-6548: Terminal elimination half-life (t1/2)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  5. PK Parameters of AKB-6548: Area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUC 0-t)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  6. PK Parameters of AKB-6548: AUC from time 0 to infinity (AUC 0-inf)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  7. AKB-6548: Apparent oral clearance (CL/F)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

  8. AKB-6548: Apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose

07

Study locations

1 site
  • Kalamazoo, Michigan 49007, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2015
First posted
Apr 9, 2015
Start
Apr 2015
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02412449
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Apr 2015
Primary completion
Apr 2015
Completion
Apr 2015
Last update
Nov 14, 2018

Study contacts

Akebia Therapeutics
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion